复发/难治性淋巴瘤患者接受PD-1阻断治疗后异基因造血干细胞移植的安全性与疗效
这项国际回顾性分析纳入39例既往接受PD-1抑制剂治疗的淋巴瘤患者,移植前中位间隔62天(7-260)。中位随访12个月后,1年2-4级和3-4级急性GVHD累积发生率分别为44%和23%,1年慢性GVHD发生率为41%。1年总生存率和无进展生存率分别为89%(95%CI 74-96)和76%(95%CI 56-87)。作者认为PD-1阻断后HSCT可行且复发率低,但早期免疫毒性风险可能增加。
要点
- 39例淋巴瘤患者PD-1阻断后行HSCT,移植前中位间隔62天(7-260)。
- 1年2-4级和3-4级急性GVHD累积发生率分别为44%和23%,慢性GVHD为41%。
- 1年总生存率89%(95%CI 74-96),无进展生存率76%(95%CI 56-87)。
核心结论
- PD-1阻断后行HSCT看似可行且复发率低,但早期免疫毒性风险可能增加,可能反映既往PD-1阻断触发的持久免疫改变。
研究设计与样本
- 国际回顾性分析,纳入39例接受过PD-1抑制剂治疗且随后行异基因造血干细胞移植的淋巴瘤患者,移植前中位间隔62天(7-260)。
主要发现
- 中位随访12个月,1年2-4级和3-4级急性GVHD累积发生率分别为44%和23%,1年慢性GVHD发生率为41%。
- 发生4例治疗相关死亡(1例肝窦阻塞综合征,3例早期急性GVHD)。
- 7例患者在移植后不久出现需长期激素治疗的非感染性发热综合征。
- 1年总生存率和无进展生存率分别为89%(95%CI 74-96)和76%(95%CI 56-87);1年复发累积发生率和非复发死亡率分别为14%(95%CI 4-29)和11%(95%CI 3-23)。
- 17例患者进行了循环淋巴细胞亚群分析,与对照相比,既往PD-1阻断治疗患者PD-1+ T细胞显著减少,调节性T细胞与常规CD4和CD8 T细胞比值降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). However, the safety and efficacy of HSCT may be affected by prior PD-1 blockade. We conducted an international retrospective analysis of 39 patients with lymphoma who received prior treatment with a PD-1 inhibitor, at a median time of 62 days (7-260) before HSCT. After a median follow-up of 12 months, the 1-year cumulative incidences of grade 2-4 and grade 3-4 acute graft-versus-host disease (GVHD) were 44% and 23%, respectively, whereas the 1-year incidence of chronic GVHD was 41%. There were 4 treatment-related deaths (1 from hepatic sinusoidal obstruction syndrome, 3 from early acute GVHD). In addition, 7 patients developed a noninfectious febrile syndrome shortly after transplant requiring prolonged courses of steroids. One-year overall and progression-free survival rates were 89% (95% confidence interval [CI], 74-96) and 76% (95% CI, 56-87), respectively. One-year cumulative incidences of relapse and nonrelapse mortality were 14% (95% CI, 4-29) and 11% (95% CI, 3-23), respectively. Circulating lymphocyte subsets were analyzed in 17 patients. Compared with controls, patients previously treated with PD-1 blockade had significantly decreased PD-1+ T cells and decreased ratios of T-regulatory cells to conventional CD4 and CD8 T cells. In conclusion, HSCT after PD-1 blockade appears feasible with a low rate of relapse. However, there may be an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD-1 blockade.
引用
- Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017. PMID: 28073785. doi:10.1182/blood-2016-09-738385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。